Calico Life Sciences, LLC

The fourth quarter of 2024 was not without setbacks for AbbVie, which took a $3.5bn impairment against the value of its 2023 buyout of Cerevel after a Phase II failure in schizophrenia, but the pharma

The amyotrophic lateral sclerosis (ALS) pipeline has suffered a series of setbacks recently and two separate candidates from AbbVie/Calico Life Sciences and Denali Therapeutics that have the same of m

Terray Therapeutics is the latest firm to score a significant heap of cash in order to develop an artificial intelligence (AI)-based drug discovery and development platform, and it is armed with what

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Terray Inks Initial Partnership With Ca